Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Express Scripts
Mallinckrodt
Colorcon
Harvard Business School

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Torcetrapib

See Plans and Pricing

« Back to Dashboard

Drug Development Status for Torcetrapib: Patents, clinical trial progress, indications

Torcetrapib is an investigational drug.

There have been 17 clinical trials for Torcetrapib. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2009.

The most common disease conditions in clinical trials are Hyperlipidemias, Hypercholesterolemia, and Hyperlipoproteinemia Type II. The leading clinical trial sponsors are Pfizer, Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA), and Dr. Reddy's Laboratories Limited.

There are nine hundred and eighty-three US patents protecting this investigational drug and ten international patents.

Recent Clinical Trials for Torcetrapib
TitleSponsorPhase
A Proof of Concept Study to Determine the Local Delivery and Efficacy of NanocortAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)Phase 1/Phase 2
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol LevelsPharmaNetPhase 2
A Safety and Efficacy Study of DRL-17822, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Patients With Abnormal Cholesterol LevelsDr. Reddy's Laboratories LimitedPhase 2

See all Torcetrapib clinical trials

Clinical Trial Summary for Torcetrapib

Top disease conditions for Torcetrapib
Top clinical trial sponsors for Torcetrapib

See all Torcetrapib clinical trials

US Patents for Torcetrapib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Torcetrapib   Start Trial Antidiabetic tricyclic compounds Merck Sharp & Dohme (Rahway, NJ)   Start Trial
Torcetrapib   Start Trial Combination therapy Boehringer Ingelheim International GmbH (Ingelheim am Rhein, DE)   Start Trial
Torcetrapib   Start Trial Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Torcetrapib   Start Trial Synthetic linear apelin mimetics for the treatment of heart failure NOVARTIS AG (Basel, CH)   Start Trial
Torcetrapib   Start Trial Monocyclic isoxazolines as inhibitors of cholesterol ester transfer protein Merck Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Torcetrapib   Start Trial Substituted pyrrolidines as G-protein coupled receptor 43 agonists Ogeda SA (Gosselies, BE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Torcetrapib

Drugname Country Document Number Estimated Expiration Related US Patent
Torcetrapib Australia 2015263620 2034-05-22   Start Trial
Torcetrapib Canada 2947781 2034-05-22   Start Trial
Torcetrapib China 106458913 2034-05-22   Start Trial
Torcetrapib European Patent Office 3145915 2034-05-22   Start Trial
Torcetrapib Japan 2017516771 2034-05-22   Start Trial
Torcetrapib South Korea 20170005861 2034-05-22   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
McKesson
Mallinckrodt
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.